Healthcare / BiotechnologyHKSE
$9.52
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-20.3M · quality 52.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
39/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.3B
P/E
95.2x
↑EV/EBITDA
39.7x
↑ROE
2.9%
↑Gross Margin
100.0%
↑Debt/Equity
0.16
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
12.0%
FCF / Net income
1.33x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $612.1M · net income $55.2M · FCF $73.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $612.1M | $612.1M | $504.0M | $19.1M | — |
| Net Income | $55.2M | $55.2M | $28.3M | $-431.6M | $-495.6M |
| EBITDA | $142.1M | $142.1M | $103.2M | $-411.0M | $-477.1M |
| EPS | 0.09 | 0.09 | 0.04 | -0.67 | -0.80 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | — |
| Operating Margin | 7.0% | 7.0% | -1.7% | -2570.3% | — |
| Net Margin | 9.0% | 9.0% | 5.6% | -2264.3% | — |
| Balance Sheet | |||||
| Debt/Equity | 0.16 | 0.16 | 0.01 | 0.02 | 0.02 |
| Current Ratio | 4.98 | 4.98 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $73.8M | $73.8M | $-20.3M | $-457.0M | $-366.6M |
| Returns | |||||
| ROE | 2.9% | 2.9% | 1.4% | -21.8% | -21.1% |
| Valuation | |||||
| P/E | 95.20 | 95.20 | 111.50 | — | — |
| EV/EBITDA | 39.72 | 39.72 | 25.50 | — | — |
| P/B | 3.17 | 3.17 | 1.48 | 1.10 | 0.79 |
| Growth & Yield | |||||
| Revenue Growth | 21.5% | 21.5% | 2544.2% | — | — |
| EPS Growth | 125.0% | 125.0% | 106.0% | 16.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
110.9%
EPS terminal req.
$0.84
Spread vs growth
14.1%
5Y implied EPS CAGR
62.6%
EPS terminal req.
$1.02
Spread vs growth
62.4%
10Y implied EPS CAGR
33.7%
EPS terminal req.
$1.65
Spread vs growth
91.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+14.0%
Start / end P/E
208.8x → 105.8x
EPS bridge
0.04 → 0.09
Residual
-61.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.